Aranesp
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia. The drug targets the erythropoietin receptor, initiating the same pathway as native erythropoietin, and triggering increased blood production in bone marrow.
TABLE OF CONTENTS
4 Product Profiles
4 Aranesp : Anemia in chronic kidney disease
20 Aranesp : Chemotherapy-induced anemia
LIST OF FIGURES
12 Figure 1: Aranesp for anemia in chronic kidney disease – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Aranesp for anemia in chronic kidney disease
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Aranesp for anemia in chronic kidney disease
16 Figure 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
27 Figure 5: Aranesp for chemotherapy-induced anemia – SWOT analysis
28 Figure 6: Datamonitor Healthcare’s drug assessment summary of Aranesp in chemotherapy-induced anemia
29 Figure 7: Datamonitor Healthcare’s drug assessment summary of Aranesp in chemotherapy-induced anemia
LIST OF TABLES
4 Table 1: Aranesp drug profile
6 Table 2: Aranesp pivotal trial data in anemia in chronic kidney disease
9 Table 3: Aranesp other late-phase trial data in anemia in chronic kidney disease
17 Table 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
21 Table 5: Aranesp drug profile
23 Table 6: Aranesp pivotal trial data in chemotherapy-induced anemia
25 Table 7: Aranesp late-phase trial data in chemotherapy-induced anemia
26 Table 8: Aranesp ongoing late-phase clinical trial in chemotherapy-induced anemia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Roxadustat 
Sign up to the